Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
Domenica Rubino, Frank L. Greenway, Usman Khalid, et al.
JAMA (2022) Vol. 327, Iss. 2, pp. 138-138
Open Access | Times Cited: 575

Showing 26-50 of 575 citing articles:

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo
Pharmaceutical Research (2022) Vol. 39, Iss. 6, pp. 1233-1248
Open Access | Times Cited: 69
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
Simon Birk Kjær Jensen, Martin Bæk Blond, Rasmus Michael Sandsdal, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102475-102475
Open Access | Times Cited: 57
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
Femin Prasad, Riddhita De, Vittal Korann, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 54
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 933-944
Closed Access | Times Cited: 54
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Thomas A. Wadden, Ariana M. Chao, Molly Moore, et al.
Current Obesity Reports (2023) Vol. 12, Iss. 4, pp. 453-473
Open Access | Times Cited: 54
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options
Arturo Cesaro, Gianantonio De Michele, Fabio Fimiani, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 48
Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?
Simon Kloock, Christian G. Ziegler, Ulrich Dischinger
Pharmacology & Therapeutics (2023) Vol. 251, pp. 108549-108549
Open Access | Times Cited: 48
Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Xunzhe Yin, Xiangyu Guo, Zuojia Liu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2844-2844
Open Access | Times Cited: 46
Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence
Natia Murvelashvili, Luyu Xie, Jeffrey N. Schellinger, et al.
Obesity (2023) Vol. 31, Iss. 5, pp. 1280-1289
Open Access | Times Cited: 43
Fecal microbiota transplantation: current challenges and future landscapes
Abbas Yadegar, Haggai Bar‐Yoseph, Tanya Monaghan, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Open Access | Times Cited: 43
Obesity and cardiovascular health
Aimee Welsh, Muhammad Hammad, Ileana L. Piña, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 8, pp. 1026-1035
Open Access | Times Cited: 41
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Heart Journal (2024)
Open Access | Times Cited: 41
Medications for Obesity
Kimberly A. Gudzune, Robert F. Kushner
JAMA (2024) Vol. 332, Iss. 7, pp. 571-571
Closed Access | Times Cited: 40
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
Yiming Mu, Xiao-lei Bao, Freddy G. Eliaschewitz, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 184-195
Closed Access | Times Cited: 38
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Henning Bliddal, Harold Bays, Sébastien Czernichow, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 17, pp. 1573-1583
Closed Access | Times Cited: 34
Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
Jianxing Zhou, You Zheng, Baohua Xu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 31
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 29
Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes
Patrick P. Gleason, Benjamin Y. Urick, Landon Marshall, et al.
Journal of Managed Care & Specialty Pharmacy (2024) Vol. 30, Iss. 8, pp. 860-867
Open Access | Times Cited: 29
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
João Carlos Locatelli, Juliene Gonçalves Costa, Andrew Haynes, et al.
Diabetes Care (2024) Vol. 47, Iss. 10, pp. 1718-1730
Open Access | Times Cited: 26
Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss
Muhammad Haseeb, Jagpreet Chhatwal, Jade Xiao, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e246221-e246221
Open Access | Times Cited: 25
Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database
Wei Chen, Peishan Cai, Wen‐Bin Zou, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 22
Effectiveness and safety of drugs for obesity
Kristina H. Lewis, Caroline E Sloan, Daniel H. Bessesen, et al.
BMJ (2024), pp. e072686-e072686
Open Access | Times Cited: 22
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Barbara McGowan, Jens Meldgaard Bruun, Matt Capehorn, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 9, pp. 631-642
Closed Access | Times Cited: 21
Pharmacotherapy for obesity: moving towards efficacy improvement
Walmir Coutinho, Bruno Halpern
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 18
Obesity management: sex-specific considerations
Tobias Kantowski, Clarissa Schulze zur Wiesch, Jens Aberle, et al.
Archives of Gynecology and Obstetrics (2024) Vol. 309, Iss. 5, pp. 1745-1752
Open Access | Times Cited: 18

Scroll to top